MALVERN, Pa. — November 20, 2025 — Leads & Copy — Neuronetics, Inc., a vertically integrated, commercial-stage medical technology and healthcare company (NASDAQ: STIM), will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Dec. 4, 2025, the company announced today.
The fireside chat is scheduled for 12:30 p.m. (ET) on Thursday, Dec. 4, 2025. Registered attendees can access the presentation via the conference portal.
Neuronetics believes that mental health is as important as physical health and is a global leader in neuroscience, delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped.
Neuronetics sells the NeuroStar Advanced Therapy System and associated treatment sessions and operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered. It is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry.
Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first-line adjunct for the treatment of MDD in adolescent patients aged 15-21.
For safety information and indications for use, visit NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
Source: Neuronetics, Inc.
